results
Jump to
28 Results Found
  • Divi’s Q2 PAT may dip 9% YoY to Rs. 363.7 cr: Emkay Oct 14, 2019 03:53 PM IST

    Divi’s Q2 PAT may dip 9% YoY to Rs. 363.7 cr: Emkay

    Net Sales are expected to increase by 5.4 percent Y-o-Y (up 16.5 percent Q-o-Q) to Rs. 1,354.7 crore, according to Emkay.

  • Divis Q3 PAT seen up 53.5% YoY to Rs. 370 cr: Sharekhan Jan 18, 2019 02:40 PM IST

    Divis Q3 PAT seen up 53.5% YoY to Rs. 370 cr: Sharekhan

    Net Sales are expected to increase by 25 percent Y-o-Y (up 1 percent Q-o-Q) to Rs. 1,297.4 crore, according to Sharekhan.

  • Divi’s lab Q3 PAT seen up 82.3% YoY to Rs. 409.6 cr: ICICI Direct Jan 11, 2019 05:30 PM IST

    Divi’s lab Q3 PAT seen up 82.3% YoY to Rs. 409.6 cr: ICICI Direct

    Net Sales are expected to increase by 26.1 percent Y-o-Y (up 1.8 percent Q-o-Q) to Rs. 1,308.2 crore, according to ICICI Direct.

  • India Inc Q2 review: Earnings breadth deteriorates; margin pressure stark Nov 13, 2018 10:52 AM IST

    India Inc Q2 review: Earnings breadth deteriorates; margin pressure stark

    Input cost pressure is being increasingly absorbed by companies as the demand environment in weakening

  • Divis Labs Q2 PAT seen up 45.7% YoY to Rs. 290 cr: HDFC Securities Oct 17, 2018 05:59 PM IST

    Divis Labs Q2 PAT seen up 45.7% YoY to Rs. 290 cr: HDFC Securities

    Net Sales are expected to increase by 15 percent Y-o-Y (up 2.9 percent Q-o-Q) to Rs. 1,020 crore, according to HDFC Securities.

  • Divis Q2 PAT seen up 39.2% YoY to Rs. 272.5 cr: Sharekhan Oct 16, 2018 07:06 PM IST

    Divis Q2 PAT seen up 39.2% YoY to Rs. 272.5 cr: Sharekhan

    Net Sales are expected to increase by 20 percent Y-o-Y (up 7.3 percent Q-o-Q) to Rs. 1,068.2 crore, according to Sharekhan.

  • Divi’s Lab Q2 PAT seen up 33% YoY to Rs. 275.1 cr: ICICI Direct Oct 12, 2018 04:37 PM IST

    Divi’s Lab Q2 PAT seen up 33% YoY to Rs. 275.1 cr: ICICI Direct

    Net Sales are expected to increase by 13.7 percent Y-o-Y (up 1.7 percent Q-o-Q) to Rs. 1,012.4 crore, according to ICICI Direct.

  • Divi’s Lab Q4 PAT may dip 2.6% YoY to Rs. 280 cr: HDFC Securities Apr 20, 2018 01:05 PM IST

    Divi’s Lab Q4 PAT may dip 2.6% YoY to Rs. 280 cr: HDFC Securities

    Net Sales are expected to increase by 6.7 percent Y-o-Y (up 9.6 percent Q-o-Q) to Rs. 1,140 crore, according to HDFC Securities.

  • Divis Labs Q2 profit seen down 1% on lower operational income and revenue Oct 30, 2017 06:18 PM IST

    Divis Labs Q2 profit seen down 1% on lower operational income and revenue

    Revenue may decline due to ongoing USFDA import alert and re-inspection in Q2 of Unit 2.

  • Divis Q3 net likely up 11%, margins may be at 37% Jan 27, 2017 04:51 PM IST

    Divis Q3 net likely up 11%, margins may be at 37%

    Street will be squarely focused on commentary on 5 observations co received on its unit 2 by USFDA, inspected from Nov 29 to December 6. Analysts expect the observations to turn either into Warning letter or import alert. Unit 2 accounts for around 70 percent of company's revenue.

  • Divis Labs Q1 profit seen up 9%; revenue & EBITDA may jump 17% Aug 12, 2016 11:18 AM IST

    Divis Labs Q1 profit seen up 9%; revenue & EBITDA may jump 17%

    Divis Laboratories' first quarter profit seen up 9 percent year-on-year to Rs 265.3 crore and revenue may jump 17 percent to Rs 948 crore, according to a CNBC-TV18 poll.

  • Divis Labs Q1 PAT seen down by 19.5% at Rs 259.3 cr: Religare Jul 16, 2016 01:14 PM IST

    Divis Labs Q1 PAT seen down by 19.5% at Rs 259.3 cr: Religare

    Sales are expected to decrease by 13.7 percent Q-o-Q (up 16.9 percent Y-o-Y) to Rs 945.1 crore, according to Religare Research.

  • Divis Q1 PAT seen down 18.9% to Rs 261.4 cr: Edelweiss Jul 14, 2016 06:20 PM IST

    Divis Q1 PAT seen down 18.9% to Rs 261.4 cr: Edelweiss

    Net Sales are expected to decrease by 15.1 percent Q-o-Q (up 15.0 percent Y-o-Y) to Rs 929.9 crore, according to Edelweiss

  • Divis Labs Q4 net seen up 10%, generic biz may support topline May 27, 2016 05:39 PM IST

    Divis Labs Q4 net seen up 10%, generic biz may support topline

    Topline growth may be on the back of increased capacity utilisation at new SEZ units and generic business. Analysts feel capacity utilisation rates should rise to 80 percent against 75 percent earlier.

  • Divis Labs Q3 profit seen up 26% on strong EBITDA, revenue Feb 05, 2016 09:44 AM IST

    Divis Labs Q3 profit seen up 26% on strong EBITDA, revenue

    Operating profit in Q3 is likely to jump 28.2 percent to Rs 364 crore and margin may expand 240 basis points to 38.4 percent compared to year-ago period.

  • Muted earnings growth likely in Q1FY14: Nirmal Bang Jul 11, 2013 11:39 AM IST

    Muted earnings growth likely in Q1FY14: Nirmal Bang

    Nirmal Bang research expects the companies in their coverage universe to post a 4.4% YoY revenue growth, a 1% decline in EBITDA and a 7.2% fall in net profit. The performance reflects demand slowdown in the economy amid a depreciating Indian rupee.

  • Here's how to play Tech Mahindra, Voltas, Divis Lab post Q4 May 23, 2013 01:51 PM IST

    Here's how to play Tech Mahindra, Voltas, Divis Lab post Q4

    Sandeep Shenoy of Anand Rathi is bullish on Tech Mahindra and expects the company to perform well ahead. He recommends buying Divis Labs on dips.

  • Pharma cos likely to post 21% EBITDA growth in Q4: MOST Apr 16, 2013 01:30 PM IST

    Pharma cos likely to post 21% EBITDA growth in Q4: MOST

    Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).

  • Good performance likely from pharma in Q3: Nirmal Bang Jan 12, 2013 03:52 PM IST

    Good performance likely from pharma in Q3: Nirmal Bang

    Nirmal Bang has come out with its earnings estimates for pharmaceutical sector for the quarter ended December 2012. The research firm feels margins of pharma companies may witness YoY expansion owing to rupee depreciation (6 percent YoY).

  • See pharma sector's Q3 topline to grow 22%: Motilal Oswal Jan 12, 2013 11:54 AM IST

    See pharma sector's Q3 topline to grow 22%: Motilal Oswal

    Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.

  • See pharma sector's Q3 adj PAT to grow 26% YoY: P Lilladher Jan 12, 2013 10:57 AM IST

    See pharma sector's Q3 adj PAT to grow 26% YoY: P Lilladher

    Prabhudas Lilladher has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects top-line growth of 24 percent YoY for its coverage universe (excluding one-offs), with EBITDA growth at a robust 24 percent YoY.

  • Earnings watch: Which pharma co is in pink of its health? Aug 08, 2012 12:34 PM IST

    Earnings watch: Which pharma co is in pink of its health?

    In an interview to CNBC-TV18 Bino Pathiparampil of IIFL shared his expectation from various pharmaceutical companies ahead for their earnings.

  • Q3 earnings: Nirmal Bang reviews Glenmark, Divi's results Jan 31, 2012 01:18 PM IST

    Q3 earnings: Nirmal Bang reviews Glenmark, Divi's results

    In an interview to CNBC-TV18, Praful Borah of Nirmal Bang Institutional Equities speak about Glenmark, Divi's results and gives his outlook going forward.

  • Pharma Q3: New launches, generic drug demand to aid growth Jan 14, 2012 01:37 PM IST

    Pharma Q3: New launches, generic drug demand to aid growth

    Pharmaceutical companies are expected to report healthy 15-25% year-on-year revenue growth in the third quarter, helped by new launches especially in the US and strong demand for generic drugs.

  • Pharmaceutical results preview for Q3FY12: Emkay Jan 10, 2012 06:34 PM IST

    Pharmaceutical results preview for Q3FY12: Emkay

    Emkay Global Financial Services has come with its December quarterly earning estimates for pharmaceutical sector. According to the research firm the sector is expected to report a growth of 18% YoY (5% QoQ) in revenues partly driven by Rupee depreciation which is likely to be 4-5% of the overall growth.

Sections